238 related articles for article (PubMed ID: 34098210)
1. Perspectives of opioid use disorder treatment providers during COVID-19: Adapting to flexibilities and sustaining reforms.
Treitler PC; Bowden CF; Lloyd J; Enich M; Nyaku AN; Crystal S
J Subst Abuse Treat; 2022 Jan; 132():108514. PubMed ID: 34098210
[TBL] [Abstract][Full Text] [Related]
2. Nothing really changed: Arizona patient experience of methadone and buprenorphine access during COVID.
Meyerson BE; Bentele KG; Russell DM; Brady BR; Downer M; Garcia RC; Garnett I; Lutz R; Mahoney A; Samorano S; Arredondo C; Andres HJ; Coles H; Granillo B
PLoS One; 2022; 17(10):e0274094. PubMed ID: 36282806
[TBL] [Abstract][Full Text] [Related]
3. Medication treatment for opioid use disorder in the age of COVID-19: Can new regulations modify the opioid cascade?
Nunes EV; Levin FR; Reilly MP; El-Bassel N
J Subst Abuse Treat; 2021 Mar; 122():108196. PubMed ID: 33221125
[TBL] [Abstract][Full Text] [Related]
4. Receipt of Telehealth Services, Receipt and Retention of Medications for Opioid Use Disorder, and Medically Treated Overdose Among Medicare Beneficiaries Before and During the COVID-19 Pandemic.
Jones CM; Shoff C; Hodges K; Blanco C; Losby JL; Ling SM; Compton WM
JAMA Psychiatry; 2022 Oct; 79(10):981-992. PubMed ID: 36044198
[TBL] [Abstract][Full Text] [Related]
5. Lessons from the First Wave of COVID-19 for Improved Medications for Opioid Use Disorder (MOUD) Treatment: Benefits of Easier Access, Extended Take Homes, and New Delivery Modalities.
Walters SM; Perlman DC; Guarino H; Mateu-Gelabert P; Frank D
Subst Use Misuse; 2022; 57(7):1144-1153. PubMed ID: 35443862
[No Abstract] [Full Text] [Related]
6. "The idea is to help people achieve greater success and liberty": A qualitative study of expanded methadone take-home access in opioid use disorder treatment.
Suen LW; Castellanos S; Joshi N; Satterwhite S; Knight KR
Subst Abus; 2022; 43(1):1143-1150. PubMed ID: 35499469
[No Abstract] [Full Text] [Related]
7. Experiences with substance use disorder treatment during the COVID-19 pandemic: Findings from a multistate survey.
Saloner B; Krawczyk N; Solomon K; Allen ST; Morris M; Haney K; Sherman SG
Int J Drug Policy; 2022 Mar; 101():103537. PubMed ID: 34871945
[TBL] [Abstract][Full Text] [Related]
8. The COVID-19 pandemic and opioid use disorder: Expanding treatment with buprenorphine, and combining safety precautions with telehealth.
Cales RH; Cales SC; Shreffler J; Huecker MR
J Subst Abuse Treat; 2022 Feb; 133():108543. PubMed ID: 34210567
[TBL] [Abstract][Full Text] [Related]
9. The impact of COVID-19 and rapid policy exemptions expanding on access to medication for opioid use disorder (MOUD): A nationwide Veterans Health Administration cohort study.
Livingston NA; Davenport M; Head M; Henke R; LeBeau LS; Gibson TB; Banducci AN; Sarpong A; Jayanthi S; Roth C; Camacho-Cook J; Meng F; Hyde J; Mulvaney-Day N; White M; Chen DC; Stein MD; Weisberg R
Drug Alcohol Depend; 2022 Dec; 241():109678. PubMed ID: 36368167
[TBL] [Abstract][Full Text] [Related]
10. Early innovations in opioid use disorder treatment and harm reduction during the COVID-19 pandemic: a scoping review.
Krawczyk N; Fawole A; Yang J; Tofighi B
Addict Sci Clin Pract; 2021 Nov; 16(1):68. PubMed ID: 34774106
[TBL] [Abstract][Full Text] [Related]
11. Understanding opportunities and challenges with telemedicine-delivered buprenorphine during the COVID-19 pandemic.
Mattocks KM; Moore DT; Wischik DL; Lazar CM; Rosen MI
J Subst Abuse Treat; 2022 Aug; 139():108777. PubMed ID: 35346533
[TBL] [Abstract][Full Text] [Related]
12. An examination of telehealth policy impacts on initial rural opioid use disorder treatment patterns during the COVID-19 pandemic.
Hughes PM; Verrastro G; Fusco CW; Wilson CG; Ostrach B
J Rural Health; 2021 Jun; 37(3):467-472. PubMed ID: 33720447
[TBL] [Abstract][Full Text] [Related]
13. Assessing the impact of social distancing measures implemented during COVID-19 pandemic on medications for opioid use disorder in West Virginia.
Haggerty T; Khodaverdi M; Dekeseredy P; Wood N; Hendricks B; Peklinsky J; Sedney CL
J Subst Abuse Treat; 2022 May; 136():108687. PubMed ID: 34903397
[TBL] [Abstract][Full Text] [Related]
14. Clinician Perspectives on Delivering Medication Treatment for Opioid Use Disorder during the COVID-19 Pandemic: A Qualitative Evaluation.
Lott AM; Danner AN; Malte CA; Williams EC; Gordon AJ; Halvorson MA; Saxon AJ; Hagedorn HJ; Sayre GG; Hawkins EJ
J Addict Med; 2023 Jul-Aug 01; 17(4):e262-e268. PubMed ID: 37579107
[TBL] [Abstract][Full Text] [Related]
15. Massachusetts Justice Community Opioid Innovation Network (MassJCOIN).
Evans EA; Stopka TJ; Pivovarova E; Murphy SM; Taxman FS; Ferguson WJ; Bernson D; Santelices C; McCollister KE; Hoskinson R; Lincoln T; Friedmann PD;
J Subst Abuse Treat; 2021 Sep; 128():108275. PubMed ID: 33483222
[TBL] [Abstract][Full Text] [Related]
16. The provision of counseling to patients receiving medications for opioid use disorder: Telehealth innovations and challenges in the age of COVID-19.
Hughto JMW; Peterson L; Perry NS; Donoyan A; Mimiaga MJ; Nelson KM; Pantalone DW
J Subst Abuse Treat; 2021 Jan; 120():108163. PubMed ID: 33298301
[TBL] [Abstract][Full Text] [Related]
17. Leveraging pharmacists to maintain and extend buprenorphine supply for opioid use disorder amid COVID-19 pandemic.
Peckham AM; Ball J; Colvard MD; Dadiomov D; Hill LG; Nichols SD; Tallian K; Ventricelli DJ; Tran TH
Am J Health Syst Pharm; 2021 Mar; 78(7):613-618. PubMed ID: 33411894
[TBL] [Abstract][Full Text] [Related]
18. Impact of COVID-19-related methadone regulatory flexibilities: views of state opioid treatment authorities and program staff.
Mitchell SG; Jester J; Gryczynski J; Whitter M; Fuller D; Halsted C; Schwartz RP
Addict Sci Clin Pract; 2023 Oct; 18(1):61. PubMed ID: 37848970
[TBL] [Abstract][Full Text] [Related]
19. Primary Care Providers' Experiences Treating Opioid Use Disorder Using Telehealth in the Height of the COVID-19 Pandemic.
Marshall SA; Siebenmorgen LE; Youngen K; Borders T; Zaller N
J Prim Care Community Health; 2024; 15():21501319241246359. PubMed ID: 38600789
[TBL] [Abstract][Full Text] [Related]
20. Provider experiences with relaxing restrictions on take-home medications for opioid use disorder during the COVID-19 pandemic: A qualitative systematic review.
Adams A; Blawatt S; MacDonald S; Finnick R; Lajeunesse J; Harrison S; Byres D; Schechter MT; Oviedo-Joekes E
Int J Drug Policy; 2023 Jul; 117():104058. PubMed ID: 37182352
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
